Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
To engineer an ideal ADC, the drug must achieve a cohesive, molecular partnership between the cellular target, antibody, cytotoxic payload and chemical linker. This development was enabled by a constantly evolving understanding of the interplay between the different ADC components and their relationship with disease biology.
Let's personalize your content